HGH Fragment 176-191
HGH Frag · Frag 176-191 · AOD-9176
Half-life
30 min
Time to Peak
15 min
Steady State
~1 days
Dose Range
200–500 mcg
Frequency
Twice daily
Overview
Synthetic peptide fragment corresponding to amino acids 176–191 of human growth hormone. Isolated specifically for fat-metabolising (lipolytic) activity of HGH without the anabolic or blood-glucose-raising effects of full-length HGH. Injected subcutaneously, typically before fasted cardio or between meals to maximise lipolytic window. NOTE: The commercial form AOD-9604 (acetylated version) is already in the catalog under uid aod_9604. This entry covers the raw peptide fragment as used by the research peptide community. Harm reduction: Does not suppress endogenous GH. No insulin-like effects. Refrigerate reconstituted peptide; use within 30 days.
Mechanism of Action
C-terminal fragment of human growth hormone (residues 176–191). Stimulates lipolysis and inhibits lipogenesis via beta-3 adrenergic receptor pathway. Does not bind IGF-1 receptor — minimal anabolic or diabetogenic activity.
Dosing Information
| Route | Dose Range | Half-life | Tmax | Frequency |
|---|---|---|---|---|
| Subcutaneous (SubQ) | 200–500 mcg | 30 min | 15 min | Twice daily, three times daily |
Storage & Handling
Refrigerated — Store lyophilised powder at -20C long-term or 4C short-term (up to 3 months). Reconstitute with bacteriostatic water. Use within 30 days of reconstitution. Protect from light.
Used in Regimens
HGH Fragment 176-191 is not currently part of any catalog regimen.
Data Sources
- Community r/steroids Compound Experience Directory
Related Tools
Track HGH Fragment 176-191 with Doseline
Reminders, medication level charts, injection site rotation, and protocol tracking — all free, all private.
Join the waitlistDoseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.